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Randomized Evaluation of Polytetrafluoroethylene-Covered
Stent in Saphenous Vein Grafts
The Randomized Evaluation of polytetrafluoroethylene COVERed stent in
Saphenous vein grafts (RECOVERS) Trial
Goran Stankovic, MD; Antonio Colombo, MD; Patrizia Presbitero, MD; Frank van den Branden, MD;
Luigi Inglese, MD; Carmelo Cernigliaro, MD; Luigi Niccoli, MD; Antonio L. Bartorelli, MD;
Paolo Rubartelli, MD; Nicholaus Reifart, MD; Guy R. Heyndrickx, MD; Kari Saunamäki, MD;
Marie Claude Morice, MD; Fabio A. Sgura, MD; Carlo Di Mario, MD; for the RECOVERS Investigators
Background—Treatment of lesions located in saphenous vein grafts (SVGs) is associated with increased procedural risk
and a high rate of restenosis.
Methods and Results—We conducted a randomized, multicenter trial to evaluate the usefulness of a polytetrafluoroeth-
ylene (PTFE)-covered stent compared with a bare stainless steel (SS) stent for prevention of restenosis and major
adverse cardiac events (MACE) in patients undergoing SVG treatment. The primary end point was angiographic
restenosis at 6 months. Secondary end points were 30-day and 6-month MACE rates, defined as the cumulative of death,
myocardial infarction (MI), and target lesion revascularization. Between September 1999 and January 2002, 301 patients
with SVG lesions were randomized to either the PTFE-covered JoStent coronary stent graft (PTFE group, n156) or
the SS JoFlex stent (control group, n145). Angiographic and procedural success rates were similar between the 2
groups (97.4% versus 97.9% and 87.3% versus 93.8%, respectively). The incidence of 30-day MACE was higher in the
PTFE group (10.9% versus 4.1%, P0.047) and was mainly attributed to MI (10.3% versus 3.4%, P0.037). The
primary end point, the restenosis rate at 6-month follow-up, was similar between the 2 groups (24.2% versus 24.8%,
P0.237). Although the 6-month non–Q-wave MI rate was higher in the PTFE group (12.8% versus 4.1%, P0.013),
the cumulative MACE rate was not different (23.1% versus 15.9%, P0.153).
Conclusions—The study did not demonstrate a difference in restenosis rate and 6-month clinical outcome between the
PTFE-covered stent and the SS stent for treatment of SVG lesions. However, a higher incidence of nonfatal myocardial
infarctions was found in patients treated with the PTFE-covered stent. (Circulation. 2003;108:37-42.)
Key Words: polytetrafluoroethylene  grafting  restenosis
Treatment of lesions located in saphenous vein grafts(SVGs) is still a challenge. Repeat surgical revascular-
ization (CABG) is feasible but is associated with higher
morbidity and mortality and less symptomatic improvement
than the initial operation.1,2 Attempts at percutaneous revas-
cularization in SVG lesions with balloon angioplasty were
limited by a relatively low procedural success rate and a high
incidence of angiographic recurrence.3,4 A randomized, sa-
phenous vein de novo trial (the SAVED trial) showed that
stent implantation in patients with focal SVG lesions im-
proved procedural success and clinical outcome compared
with balloon angioplasty.5 However, even with the use of
stents, treatment of SVG lesions is associated with a high
incidence of acute complications, principally distal emboli-
zation and periprocedural myocardial infarction (MI), be-
cause of the more friable atherosclerotic or thrombotic
components of the SVG lesions.6–12 The polytetrafluoroeth-
ylene (PTFE)-covered stent was recently proposed as a new
treatment option for SVG lesions with the rationale that a
covered stent would be able to entrap friable degenerated
material, decrease the probability of distal embolization, and
reduce neointimal proliferation.13–16
We therefore designed the Randomized Evaluation of
polytetrafluoroethylene COVERed stent in Saphenous vein
grafts (RECOVERS) trial to compare angiographic restenosis
rates and early and late clinical outcome between the PTFE-
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covered stent and the bare stent in patients undergoing SVG
intervention.
Methods
Patient Population
The study was a prospective, randomized trial conducted from
September 1999 to January 2002 at 20 medical centers, primarily
located in Europe (see Appendix). The protocol was reviewed and
approved by the medical ethics committee at each participating
center, and all patients gave written informed consent.
Patients were eligible for the study if they were at least 18 years
old, were not pregnant, had a diagnosis of stable or unstable angina
or documented silent ischemia, and had an ejection fraction 35%.
The angiographic criteria for inclusion were the presence of a
maximum of 2 de novo lesions in an SVG or in 2 vein grafts, with
a reference diameter between 2.5 and 5.5 mm and a stenosis of
50% and 100%, that required no more than one 26-mm-long
covered or bare stent each, as estimated visually.
Patients were not eligible for enrollment if they had an MI within
the past 3 days or had a known allergy to the study medications.
Angiographic exclusion criteria were a single remaining bypass graft
(single remaining circulation), intention to treat native vessels,
presence of large thrombus (50% vessel diameter) in the target
lesion, or a lesion located close to side anastomosis.
Randomization
Treatment assignment was determined by computer-generated ran-
domization codes distributed in sealed envelopes to each participat-
ing center. Patients were randomly assigned to the groups in a 1:1
ratio. Separate envelopes permitted stratification according to oper-
ator’s decision to use glycoprotein IIb/IIIa receptor blockers on an
elective basis.
Study Device and Interventional Procedure
The JoStent coronary stent graft (Jomed) consists of 2 coaxially
aligned stainless steel stents (surgical 316 L) that encompass a
microporous PTFE membrane between them in a sandwich-like
configuration.13 Overall wall thickness is 0.30 mm, and mounted
profile is 1.6 mm. The stent graft was available in lengths of 9, 12,
16, 19, and 26 mm and a maximum achievable diameter of 5.0 mm.
The longitudinal shortening of the stent on expansion is 3%.
In either arm, lesion predilatation was performed with an under-
sized balloon. The PTFE-covered stent was then hand-crimped on a
balloon sized 1.1:1 to SVG diameter based on angiography. High-
pressure postdilatation was suggested, and the criterion for optimal
stent deployment was a final residual diameter stenosis of 20%.
If dissection or plaque shift occurred at the edge of the stent,
additional stents were implanted according to initial randomization.
Use of intravascular ultrasound to guide the procedure was left to the
discretion of the operator.
Concomitant Medications
All patients were premedicated with aspirin 325 mg/d and ticlopidine
500 mg/d or clopidogrel 75 mg/d, which was begun at least at the
time of randomization. During the procedure, patients received
intravenous heparin to maintain an activated clotting time of 250 to
300 seconds. Platelet glycoprotein IIb/IIIa receptor blockers were
used at the discretion of the operator.
All patients received aspirin (at least 100 mg/d) indefinitely.
Patients who received the PTFE-covered stent were treated with
ticlopidine 500 mg/d or clopidogrel 75 mg/d for 3 months, whereas
patients who received the bare stainless steel (SS) stent were treated
for 1 month.
Angiographic Analysis
From 2 orthogonal views, the diameter of the reference vessel,
minimal luminal diameter, and target lesion length were determined
at baseline, after procedure, and at follow-up with a validated
edge-detection program (CMS version 4.0, MEDIS). In addition, the
acute gain, late loss, and late-loss index were calculated. Lesions
were characterized according to the modified American College of
Cardiology/American Heart Association classification. Long lesions
were defined as a single continuous narrowing longer than 15 mm.
Tandem lesions were defined as lesions in the same vessel that were
separated by 15 mm of nondiseased segment. Degenerated SVG
was defined as a graft that had a lesion longer than 30 mm and was
associated with the presence of thrombus or irregular lumen con-
tours. Distal embolization was defined as angiographic cutoff of a
distal branch or vessel at any point during the procedure or decreased
flow in a distal vessel that was previously patent in the absence of an
occlusion at the site of the target lesion.17 No reflow was defined as
Thrombolysis In Myocardial Infarction (TIMI) flow grade 1 that
was not due to dissection or high-grade residual stenosis adjacent to
the target lesion.
Study End Points and Definitions
The primary end point was angiographic restenosis, defined as
stenosis of 50% by quantitative coronary angiography at 6-month
follow-up angiography or earlier. Secondary end points were 30-day
and 6-month major adverse cardiac events (MACE), defined as the
composite of death, non–Q-wave MI, Q-wave MI, and target lesion
revascularization (CABG and repeat percutaneous coronary
intervention).
Angiographic success was defined as final diameter stenosis of
50%. Procedural success was defined as angiographic success
without in-hospital MACE.
MI was defined as the occurrence of an elevated creatine kinase
(CK)–MB fraction 3 times the upper limit of normal (standardized
to the normal range of each clinical site). Patients with enzymatic
elevation were further stratified into those with and without appear-
ance of pathological Q waves on serial ECGs. Cardiac enzymes
(total CK and CK-MB) were measured before treatment and at 4 to
8 hours after the procedure; further determinations were required if
either CK or CK-MB was elevated.
Statistical Analysis
The study was designed to have a power of 80% to reject the null
hypothesis of no difference between the treatment groups, with a 5%
level of significance in 2-tailed tests. On the assumption that the
angiographic restenosis rate would be 35% in the SS stent group5 and
17% in the PTFE-covered stent group,14 it was determined that 300
patients would be needed to detect that difference. Comparisons
between the 2 treatment groups were performed on an intention-to-
treat basis.
The data are presented as numbers and percentages or meanSD.
Categorical variables were compared with the 2 test or Fisher’s
exact test when appropriate. Continuous variables were compared
with the use of Student’s t test or ANOVA. A stepwise multivariable
logistic model of the primary and secondary end points was
constructed in which the dependent variables were angiographic
restenosis or incidence of MACE at 6-month follow-up and the
independent variables selected were clinical, angiographic, and
procedural covariates. The results are presented as odds ratios with
95% CIs. A 2-tailed probability value of 0.05 or less was considered
significant. All statistical analysis was performed with SAS version
6.12 (SAS Institute).
Results
Between September 1999 and January 2002, 301 patients
were enrolled at 20 medical centers, primarily in Europe. One
hundred fifty-six patients were randomized to the PTFE-
covered stent and 145 patients to the SS stent.
Baseline clinical characteristics of the 2 groups were well
matched (Table 1). Overall, 85% of the patients were men,
and the mean age was 66 years. The clinical profile showed
a high percentage of patients with a history of MI (57%) and
unstable angina (48%), with the expected prevalence of
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diabetes, hypercholesterolemia, and hypertension. The age of
the treated grafts was 9.9 years in the PTFE group and 9.1
years in the SS group (P0.21).
Angiographic and procedural characteristics are shown in
Tables 2 through 4. Except for a higher prevalence of ostial
lesion location in the control group, baseline lesion charac-
teristics were similar in the 2 groups. Stents were successfully
implanted in 152 patients in the PTFE group (97.4%) and 142
patients in the SS group (97.9%), with a mean balloon
diameter of 3.90.6 and 3.80.5 mm, respectively,
(P0.08) and an average maximum inflation pressure of
18.23.9 and 16.03.7 atm, respectively (P0.0001). Post-
dilatation after stent deployment was performed in 97 lesions
of PTFE group and 80 lesions of the control group. The final
minimal luminal diameter and acute gain were similar in the
2 groups. There was also no difference in the incidence of
dissections and transient occlusions or in the occurrence of
thrombus, distal embolization, or angiographic “no reflow.”
Glycoprotein IIb/IIIa inhibitors were used in 31% of patients
in the PTFE group and 29% in the SS group (P0.73).
Procedural success was comparable between the 2 groups
(87.3% versus 93.8% in the PTFE and SS group, respectively;
P0.08). There were no patients with acute stent thrombosis,
whereas subacute stent thrombosis occurred in 2 patients in
the PTFE group (1 of them had non–Q-wave MI) and none of
the patients in the SS group.
TABLE 1. Baseline Clinical Characteristics
PTFE Group
(n156)
SS Group
(n145) P
Age, y (range) 669 (37–87) 678 (42–85) 0.62
Male gender 136 (87.2) 121 (83.4) 0.36
Diabetes mellitus 39 (26.2) 39 (28.0) 0.82
Hypercholesterolemia* 114 (73.1) 103 (71.0) 0.80
Hypertension 96 (61.5) 90 (62.1) 0.82
Family history of CAD 66 (42.3) 55 (37.9) 0.62
Current or ex-smoker 93 (59.6) 89 (61.4) 0.58
Prior MI 90 (57.7) 80 (55.2) 0.56
Prior stroke 10 (6.4) 5 (3.4) 0.37
Prior PTCA 46 (29.5) 37 (25.5) 0.47
Clinical presentation 0.58
Unstable angina 76 (48.8) 69 (47.6)
Stable angina 62 (39.7) 62 (42.8)
Silent ischemia 18 (11.5) 14 (9.6)
Ejection fraction, % 5612 5512 0.82
Age of the SVG, y 9.95.0 9.15.5 0.21
CAD indicates coronary artery disease.
Values are numbers and percentages of patients or meanSD.
*Total cholesterol 6.5 mmol/L.
TABLE 2. Baseline Angiographic Characteristics
PTFE Group
(n166)
SS Group
(n156) P
Target graft distribution 0.40
SVG–LAD 53 (31.9) 39 (25.0)
SVG–RCA 48 (28.9) 42 (26.9)
SVG–LCx 51 (30.7) 59 (37.8)
SVG–sequential 14 (8.5) 16 (10.3)
Target lesion location 0.02
Ostial 51 (30.7) 68 (43.6)
Body 115 (69.3) 88 (56.4)
Tandem lesions 31 (18.7) 20 (12.8) 0.20
ACC/AHA type B2/C* 107 (64.5) 96 (61.5) 0.67
Degenerated graft 68 (40.9) 51 (32.7) 0.22
TIMI flow grade 0.79
1 7 (4.2) 9 (5.8)
2 49 (29.5) 47 (30.1)
3 110 (66.3) 100 (64.1)
LAD indicates left anterior descending coronary artery; LCx, left circumflex
coronary artery; and RCA, right coronary artery.
Values are numbers and percentages of lesions or meanSD.
*Modified American College of Cardiology/American Heart Association
(ACC/AHA) lesion classification.
TABLE 3. Procedural Characteristics
PTFE Group
(n166)
SS Group
(n156) P
Stent length, mm 16.95.4 16.65.4 0.59
Balloon diameter, mm 3.930.65 3.810.55 0.08
Inflation pressure, atm 18.23.9 16.43.7 0.0001
Dissection 14 (8.4) 7 (4.5) 0.18
Transient occlusion 2 (1.2) 0 0.49
Thrombus 18 (10.8) 10 (6.4) 0.22
Distal embolization 4 (2.4) 4 (2.6) 0.99
No reflow 9 (5.4) 3 (1.9) 0.14
Values are meanSD and numbers and percentages of lesions.
TABLE 4. Quantitative Coronary Angiography Analysis
PTFE Group
(n166)
SS Group
(n156) P
Baseline
Reference diameter, mm 3.360.75 3.280.71 0.73
MLD, mm 1.110.54 1.130.54 0.74
Diameter stenosis, % 67.713.4 65.614.0 0.17
Mean lesion length, mm 11.976.7 11.837.86 0.86
After procedure
Reference diameter, mm 3.730.69 3.610.69 0.12
MLD, mm 3.310.57 3.180.69 0.07
Diameter stenosis, % 10.98.5 12.08.2 0.24
Acute gain, mm 2.190.68 2.080.67 0.16
Six-month follow-up, n/n (%) 132/166 (79.5) 125/156 (80.1)
Reference diameter, mm 3.540.61 3.400.63 0.07
MLD, mm 2.371.27 2.201.09 0.26
Diameter stenosis, % 34.134.1 36.728.3 0.51
Late loss, mm 0.951.15 0.981.03 0.86
Loss index 0.470.64 0.510.62 0.65
Binary restenosis rate, n/n (%) 32/132 (24.2) 31/125 (24.8) 0.24
MLD indicates minimal luminal diameter.
Values are meanSD, except where otherwise indicated.
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Early and 6-Month Outcome
Clinical events that occurred in the hospital, during the first
month after intervention, and at 6-month follow-up are listed
in Table 5. The incidence of 30-day MACE was higher in the
PTFE group (10.9% versus 4.1%, P0.047) and was mainly
attributed to a higher incidence of MI (10.3% versus 3.4%,
P0.037).
Six-month clinical follow-up was obtained for all patients.
Although the cumulative incidence of MACE was not differ-
ent between the 2 groups (23.1% versus 15.9%, P0.153),
the incidence of MI was higher in the PTFE group (14.1%
versus 5.5%, P0.022) and was mainly accounted for by the
incidence of non–Q-wave MI (12.8% versus 4.1%,
P0.013).
A total of 242 patients (81%) with 257 lesions (80%)
underwent repeat angiography at 6-month follow-up. The
primary end point, the binary restenosis rate, was similar in
the 2 groups (25.0% versus 27.2% of patients, P0.809, and
24.2% versus 24.8% of lesions, P0.237, in the PTFE and
control groups, respectively). The pattern of restenosis in
lesions treated with the PTFE and SS stents, respectively, was
as follows: edge (37.5% versus 6.5%, P0.008), diffuse
(9.4% versus 45.2%, P0.004), and occlusive (53.1% versus
48.3%, P0.799). Among the 14 patients in the PTFE group
with occlusive restenosis, 6 patients had follow-up MACE (4
patients had non–Q-wave MI after discontinuation of ticlopi-
dine after 3 months, and 2 patients had re-PTCA). Among the
13 patients in the SS group, only 1 had follow-up non–Q-
wave MI (P0.077).
Multivariate Analysis
Multivariate regression analysis identified the following pre-
dictors of the occurrence of cumulative 6-month MACE: use
of PTFE stents (OR 2.19, 95% CI 1.16 to 4.13, P0.02) and
lesion length (OR 1.95, 95% CI 1.92 to 1.99, P0.02). There
were no predictors of angiographic restenosis.
Discussion
The results of this trial show similar 6-month outcomes with
regard to restenosis rate, death, and need for repeat revascu-
larization in patients with SVG disease treated with a PTFE-
covered stent or an SS stent. However, 30-day MACE and the
6-month MI rate were higher in patients treated with the
PTFE-covered stent.
Treatment of SVG lesions is associated with a high
incidence of acute complications, principally periprocedural
MI.6–12 The risk of developing CK-MB elevation is higher
during SVG than during native coronary intervention, mainly
because of friable atherosclerotic or thrombotic components
of the SVG lesions. Thrombus has been documented by
angioscopy in up to 70% of vein graft lesions undergoing
treatment.18 Hong et al10 reported in their study that after an
otherwise successful SVG intervention, major CK-MB ele-
vation (defined as 5 times the normal range) occurred in
15% of patients and was associated with a significantly
increased 1-year cardiac mortality rate compared with a
minor rise or normal postprocedural CK-MB values (11.7%
versus 6.5% and 4.8%, P0.05, respectively).
In an attempt to improve the outcome of intervention in
stenotic vein grafts, several approaches and adjunctive phar-
macological regimens have been studied, but with the excep-
tion of distal protection devices, none showed a clear benefit
in reducing the incidence of distal embolization, especially in
complex lesions.8,19–23 The PTFE-covered stent was recently
proposed as a new treatment option for SVG lesions, with the
rationale that a covered stent would entrap friable degener-
ated material and decrease the risk of distal embolization.13–16
Another important finding derived from observational studies
was a reduction of angiographic restenosis after SVG treat-
ment with PTFE-covered stents compared with historical
controls.13,14 A possible explanation for this reduction was
that endoluminal sealing of the vessel wall with a membrane-
covered stent prevents the exposure of underlying atheroma-
tous tissue to circulatory macrophages, the role of which is
important in initiating the restenotic process.13
However, the present study failed to support those prelim-
inary data. Although the 10.9% 30-day event rate in patients
treated with the PTFE-covered stent was similar to that
expected from historical controls, the inferiority compared
with the control group is disturbing. Our ability to discern the
mechanism is unclear, but possible explanations for the lack
of the reduction in restenosis and MACE rate could be edge
TABLE 5. Clinical Outcome
PTFE Group
(n156)
SS Group
(n145) P
In-hospital MACE 16 (10.3) 6 (4.1) 0.069
Death 0 1 (0.7) 0.970
MI 15 (9.6) 5 (3.4) 0.055
Non–Q-wave 13 (8.3) 4 (2.8) 0.065
Q-wave 2 (1.3) 1 (0.7) 0.605
TLR 2 (1.3) 0 0.511
PCI 2 (1.3) 0 0.511
CABG 0 0 NA
30-Day MACE* 17 (10.9) 6 (4.1) 0.047
Death 0 1 (0.7) 0.971
MI 16 (10.3) 5 (3.4) 0.037
Non–Q-wave 14 (8.9) 4 (2.8) 0.042
Q-wave 2 (1.3) 1 (0.7) 0.605
TLR 2 (1.3) 0 0.511
PCI 2 (1.3) 0 0.511
CABG 0 0 NA
6-Month MACE† 36 (23.1) 23 (15.9) 0.153
Death 4 (2.6) 4 (2.8) 0.917
MI 22 (14.1) 8 (5.5) 0.022
Non–Q-wave 20 (12.8) 6 (4.1) 0.013
Q-wave 2 (1.3) 2 (1.4) 0.941
TLR 15 (9.6) 12 (8.3) 0.838
PCI 13 (8.3) 10 (6.9) 0.811
CABG 2 (1.3) 2 (1.4) 0.941
PCI indicates percutaneous coronary intervention; TLR, target lesion revas-
cularization.
Values are numbers and percentages of patients.
*Cumulative 30-day MACE; †cumulative 6-month MACE.
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proliferation, which is able to extend into the stent, or small
disruptions of the PTFE membrane during stent deployment.
Edge restenosis, which was a predominant pattern of reste-
nosis in the PTFE group compared with diffuse restenosis in
the control group, may imply a more favorable clinical
outcome with further refinement in the delivery system to
limit any trauma outside the stent.
In the present study, mean balloon size and inflation
pressure were higher in the PTFE group, but according to
prior experience, high-pressure inflations (16 to 20 atm) are
necessary to achieve full expansion of the hand-mounted
PTFE stent.13 The aggressive approach used to deploy and
postdilate the PTFE stents may have contributed to the
increase in the incidence of in-hospital MIs in the PTFE
group. Elsner et al13 reported that follow-up intravascular
ultrasound interrogation demonstrated that neointimal prolif-
eration occurs predominantly at the stent edges, without
evidence of gross PTFE membrane disruption. However,
possible microscopic alterations of the membrane structure
during balloon expansion and late accumulation of the throm-
botic material cannot be ruled out.24
A disturbing feature has been the late occurrence of
non–Q-wave MI in the PTFE group. Between the first month
and the sixth month, 6 patients had non–Q-wave MI in the
PTFE group (4 of whom had angiographically documented
total occlusions). Delayed reendothelialization of the PTFE-
covered stents25 predisposing to thrombotic occlusion can
help to explain this finding.
Conclusions
Unlike previous experiences in observational studies, this
trial did not demonstrate a beneficial effect of the PTFE stent
for SVG treatment. In the present study, SVG interventions
with PTFE-covered stents had similar procedural success and
in-hospital major complication rates, as well as similar
6-month clinical outcomes compared with bare SS stents.
However, a higher incidence of nonfatal MIs was found in
patients treated with the PTFE-covered stent.
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